Premium
P1‐195: Functional magnetic resonance imaging activation patterns in cognitively normal elderly, amnestic, and non‐amnestic mild cognitive impairment during a recognition memory task
Author(s) -
Machulda Mary M.,
Senjem Matthew L.,
Smith Glenn E.,
Ivnik Robert J.,
Boeve Bradley F.,
Knopman David S.,
Petersen Ronald C.,
Jack Clifford R.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.783
Subject(s) - functional magnetic resonance imaging , posterior cingulate , neuroscience , amnesia , audiology , psychology , thalamus , fusiform gyrus , cognitive impairment , hippocampus , memory impairment , neuroimaging , gyrus , medicine , cognition , cognitive psychology
primary endpoint of progression to probable or possible AD. The association between BDI scores and progression to AD was explored using Cox proportional hazard regression. Kaplan-Meier survival analysis was used to study the rate of progression to dementia among the 3 treatment arms. Results: Cox proportional hazards regression, controlling for age at baseline, gender, apolipoprotein (ApoE) genotype, and NYU paragraph delayed recall score, showed that BDI score was significantly associated with progression to AD (p .03). Each point higher on the BDI was associated with 3% higher hazard of progression to AD (hazard ratio 1.03, 95% confidence interval 1.00-1.06). The sample was then stratified into depressed (BDI score 10; n 208) and non-depressed (BDI 10; m 548). Within the depressed group, Kaplan-Meier survival analysis and pointwise z-tests showed that the rate of progression to AD was significantly lower for the donepezil group than the pooled vitamin E and placebo groups at 1.7 years (p .023) and at 2.2 years (p .025). The difference remained robust and marginally significant at 2.7 years (p .070). The survival curves between the 3 treatment groups across the 36-month study did not differ within the non-depressed participants. Conclusions: The presence of depression was predictive of progression from aMCI to AD. Donepezil treatment delayed the time to progression to AD in a subgroup of depressed aMCI subjects. Donepezil treatment appeared to have a modulating effect on the increased risk of AD conferred by the presence of depressive symptoms.